Aytu BioPharma (NASDAQ:AYTU) Raised to “Hold” at Zacks Research

Aytu BioPharma (NASDAQ:AYTU) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Thursday,Zacks.com reports.

A number of other analysts have also recently commented on AYTU. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Monday, July 6th. Ascendiant Capital Markets lifted their price objective on Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a research report on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Aytu BioPharma has an average rating of “Hold” and a consensus target price of $10.75.

Aytu BioPharma Trading Up 3.5%

NASDAQ:AYTU opened at $2.38 on Thursday. Aytu BioPharma has a 52 week low of $1.65 and a 52 week high of $3.07. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.00 and a current ratio of 1.12. The firm’s fifty day moving average is $2.21 and its 200-day moving average is $2.37. The firm has a market cap of $25.54 million, a P/E ratio of -0.52 and a beta of 0.25.

Aytu BioPharma (NASDAQ:AYTU) last announced its earnings results on Wednesday, May 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09). The firm had revenue of $12.41 million for the quarter, compared to the consensus estimate of $12.05 million. Aytu BioPharma had a negative return on equity of 69.93% and a negative net margin of 60.17%. Equities analysts expect that Aytu BioPharma will post -0.73 earnings per share for the current year.

Institutional Trading of Aytu BioPharma

Several large investors have recently modified their holdings of AYTU. BlackRock Inc. acquired a new stake in shares of Aytu BioPharma during the 2nd quarter worth approximately $49,000. Rothschild Wealth LLC acquired a new position in shares of Aytu BioPharma during the 4th quarter valued at $52,000. Dimensional Fund Advisors LP bought a new position in Aytu BioPharma during the third quarter worth $58,000. XTX Topco Ltd bought a new position in Aytu BioPharma during the fourth quarter worth $67,000. Finally, DRW Securities LLC acquired a new stake in Aytu BioPharma in the fourth quarter worth $76,000. Institutional investors and hedge funds own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.